Found: 14
Select item for more details and to access through your institution.
Aberrant Expression of and Cell Death Induction by Engagement of the MHC-II Chaperone CD74 in Anaplastic Large Cell Lymphoma (ALCL).
- Published in:
- Cancers, 2021, v. 13, n. 19, p. 5012, doi. 10.3390/cancers13195012
- By:
- Publication type:
- Article
A peculiar case of primary central nervous system T-cell lymphoma with indolent behavior.
- Published in:
- 2023
- By:
- Publication type:
- Letter
The cell-cycle regulator c-Myc is essential for the formation and maintenance of germinal centers.
- Published in:
- Nature Immunology, 2012, v. 13, n. 11, p. 1092, doi. 10.1038/ni.2418
- By:
- Publication type:
- Article
Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma.
- Published in:
- Nature Immunology, 2006, v. 7, n. 2, p. 207, doi. 10.1038/ni1285
- By:
- Publication type:
- Article
Subsequent malignancies among long-term survivors of Hodgkin lymphoma and non-Hodgkin lymphoma: a pooled analysis of German cancer registry data (1990-2012).
- Published in:
- British Journal of Haematology, 2017, v. 177, n. 2, p. 226, doi. 10.1111/bjh.14530
- By:
- Publication type:
- Article
BAY 43-9006/Sorafenib blocks CSF1R activity and induces apoptosis in various classical Hodgkin lymphoma cell lines.
- Published in:
- British Journal of Haematology, 2011, v. 155, n. 3, p. 398, doi. 10.1111/j.1365-2141.2011.08685.x
- By:
- Publication type:
- Article
Derepression of an endogenous long terminal repeat activates the CSF1R proto-oncogene in human lymphoma.
- Published in:
- Nature Medicine, 2010, v. 16, n. 5, p. 571, doi. 10.1038/nm.2129
- By:
- Publication type:
- Article
Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B cell non-Hodgkin lymphoma.
- Published in:
- 2021
- By:
- Publication type:
- Correction Notice
Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
- Published in:
- 2021
- By:
- Publication type:
- Correction Notice
Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
- Published in:
- Investigational New Drugs, 2020, v. 38, n. 5, p. 1472, doi. 10.1007/s10637-020-00916-3
- By:
- Publication type:
- Article
Graded Elevation of c-Jun in Schwann Cells In Vivo: Gene Dosage Determines Effects on Development, Remyelination, Tumorigenesis, and Hypomyelination.
- Published in:
- Journal of Neuroscience, 2017, v. 37, n. 50, p. 12297, doi. 10.1523/JNEUROSCI.0986-17.2017
- By:
- Publication type:
- Article
Interphase cytogenetic analysis of distinct X-chromosomal translocation breakpoints in synovial sarcoma.
- Published in:
- Journal of Pathology, 1995, v. 175, n. 4, p. 391, doi. 10.1002/path.1711750405
- By:
- Publication type:
- Article
Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1.
- Published in:
- International Journal of Cancer, 2002, v. 97, n. 3, p. 278, doi. 10.1002/ijc.1610
- By:
- Publication type:
- Article
Loss of bHLH transcription factor E2A activity in primary effusion lymphoma confers resistance to apoptosis.
- Published in:
- British Journal of Haematology, 2007, v. 137, n. 4, p. 342, doi. 10.1111/j.1365-2141.2007.06583.x
- By:
- Publication type:
- Article